Who are TT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): COVAX only (1st and 2nd dose), Inactivated SARS-CoV-2 Vaccine (Vero cell）, CCP, Ad26.COV2.S vaccine, AntiCov-220, BNT162b2 (2025/2026 formulation).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TT (TT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

marketed Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

TT (TT) — CanSino Biologics Inc.. TT is a recombinant adenovirus type 5 vector-based vaccine that expresses the SARS-CoV-2 spike protein to elicit immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TT TARGET	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Inactivated SARS-CoV-2 Vaccine (Vero cell）	Inactivated SARS-CoV-2 Vaccine (Vero cell）	Sinovac Research and Development Co., Ltd.	marketed	inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
AntiCov-220	AntiCov-220	Nguyen Thi Trieu, MD	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
BNT162b2 (2025/2026 formulation)	bnt162b2-2025-2026-formulation	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

Janssen Vaccines & Prevention B.V. · 5 drugs in this class
University of Oxford · 3 drugs in this class
Crucell Holland BV · 3 drugs in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
Bharat Biotech International Limited · 2 drugs in this class
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
Samia Hassan El-Shishtawy · 1 drug in this class
University Medicine Greifswald · 1 drug in this class
Aeras · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TT — Competitive Intelligence Brief. https://druglandscape.com/ci/tt. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing